Genentech submits sNDA for Venclexta for an AML indication

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Genentech has submitted an sNDA to the FDA for Venclexta (venetoclax), in combination with a hypomethylatin agent or in combination with low dose cytarabine, for treatment of people with previously untreated acute myeloid leukemia who are ineligible for intensive chemotherapy.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Congress settled the FY26 question in February, with NCI receiving $7.352 billion, an increase of $128 million over the prior year. After a year in which cancer center directors spent an extraordinary share of their leadership attention defending the research enterprise, that outcome deserves to be called what it was: a win.
Harold P. Freeman, a surgeon who started his career in Harlem, where, in addition to performing surgeries, he pioneered the system of patient navigation, and who studied health disparities and served as president of the American Cancer Society and chair of the President’s Cancer Panel, died on Aug. 11. He was 93.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login